SCHEMBL3967524

SCHEMBL3967524

COCCOc1ccc(C=O)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.61
ALDH1A1 P00352 14/20 0.55
HPGD P15428 8/20 0.55
MEN1 O00255 2/20 0.55
POLB P06746 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 8/20 0.50
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 1/20 0.47
CYP2C9 P11712 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
HSP90AA1 P07900 1/20 0.44
AOX1 Q06278 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20529049 0.87 FDPS (0.61) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL2610707 0.85 ALDH1A1 (0.56) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL1443525 0.85 FDPS (0.54) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL482374 0.85 FDPS (0.77) FDPSALDH1A1HPGDMAPTLMNA
SCHEMBL20489952 0.84 FDPS (0.54) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL10291447 0.84 FDPS (0.53) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL1931812 0.82 FDPS (0.50) FDPSALDH1A1HPGDMEN1POLB
SCHEMBL1515797 0.82 FDPS (0.78) FDPSALDH1A1HPGDMAPTLMNA
SCHEMBL2201517 0.82 FDPS (0.90) FDPSALDH1A1HPGDMAPTLMNA
SCHEMBL5455295 0.82 FDPS (0.63) FDPSALDH1A1HPGDMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2025-10-23 US disclosed
US-12234231-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2025-02-25 US disclosed
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103368-A EIF4E inhibitors and uses thereof 皮克医疗公司 2024-05-28 CN disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
WO-2023028235-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-03-02 WO disclosed
CN-110041331-B Styrylxanthine derivative and use thereof 广东东阳光药业有限公司 2020-08-07 CN disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 FDPS 611/4885ALDH1A1 198/4885HPGD 483/4885
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FDPS 942/4885ALDH1A1 4776/4885HPGD 4535/4885
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FDPS 942/4885ALDH1A1 4776/4885HPGD 4535/4885
US-12234231-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 FDPS 942/4885ALDH1A1 4776/4885HPGD 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.